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Abstract
Pertussis incidence is rising in almost every country where acellular pertussis (aP) vaccines have been introduced,
and is occurring across all age groups from infancy to adulthood. The key question is why? While several known
factors such as waning of immunity, detection bias due to more sensitive tests and higher awareness of the disease
among practitioners, and evolutionary shifts among B. pertussis all likely contribute, collectively, these do not
adequately explain the existing epidemiologic data, suggesting that additional factors also contribute. Key amongst
these is recent data indicating that the immune responses induced by aP vaccines differ fundamentally from those
induced by the whole cell pertussis (wP) vaccines, and do not lead to mucosal immunity. If so, it appears likely that
differences in how the two categories of vaccines work, may be pivotal to our overall understanding of the
pertussis resurgence.
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Background
Ideally, vaccines should possess two key attributes: 1)
Direct protection of the vaccinee by creating endogen-
ous immunity rendering him/her resistant to the disease
in question; and 2) Indirect protection of individuals that
were not vaccinated, by preventing circulation of the
pathogen. This is achieved by immune responses that
also block acquisition, replication and transmission of
the pathogen in or from the host, regardless of whether
that infection actually led to clinical illness. The former
protects individuals in a population from developing
symptomatic disease, but that is distinct from whether
infections per se are blocked. The latter hinders the
pathogen’s movement through a population, and is the
mechanism that leads to herd effect [1].
Perhaps the best example of this latter feature were
the conjugated protein-polysaccharide vaccines targeting
Streptococcus pneumoniae, Haemophilus influenzae type
B, and Neisseria meningitidis. In each case, introduction
of the vaccine led to a steep decline in clinical disease by
vaccine serotypes/groups among those vaccinated, but
also a significant decline among the non-vaccinated
population, indicating herd effects. In each case, the crit-
ical mechanism underlying this herd effect was a reduc-
tion in nasopharyngeal carriage, which is itself mediated
by mucosal immunity [2–7].
The resurgence of Whooping cough, caused by Borde-
tella pertussis, to many parts of the world, is a subject of
great concern and debate. Part of this uncertainty rests
in the limitations of our knowledge of pertussis disease
pathogenesis and how natural or vaccine induced im-
munity impedes pathogen acquisition, replication, and
movement through populations. Pertussis is classically
described as a prolonged illness of paroxysmal coughs
ending with an inspiratory whooping sound and post-
tussive emesis. In the pre vaccine era the disease was re-
sponsible for hundreds of thousands of pertussis cases a
year with severe or fatal cases concentrated among very
young infants. From the 1950’s widespread immunization
of children in the US with the whole cell (wP) pertussis
vaccine led to a 99% reduction in pertussis cases, but not
in complete elimination of the disease [8].
But while effective, the modest reactogenicity of wP
vaccines and concerns about possible rare neurologic ad-
verse events that might have been linked to wP vaccines
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prompted a need for a new, safer vaccine to replace it
[9]. Following a lengthy development process, in 1997
the US switched to acellular vaccines (aP), which are far
less reactogenic, and, based on early head to head clin-
ical trials comparing the aP with the wP vaccines, ap-
peared to be as protective as the wP. However, the wP
vaccine chosen by the CDC to be used in those trials,
manufactured by Connaught, was later found to be one
of the most poorly immunogenic of available wP vac-
cines [10]. Several years later an increase in incidence of
pertussis in children aged 7–10 years was seen, the first
birth cohort to receive the aP vaccines [11]. By 2014
there were more than 32,000 cases reported in the US,
the highest incidence since the 1950s (Fig. 1) [8, 12].
Other countries who also switched from wP to aP vac-
cines, including the UK, Australia, Canada, Spain,
Belgium, and the Czech Republic had the same experi-
ence, with a rise in pertussis incidence after a 5–10 year
lag from the wP to aP vaccine switch.
The key question, and the focus of this paper, is why?
Since the resurgence of pertussis has occurred in almost
every country where aP vaccines replaced wP vaccines,
it cannot be assumed to be coincidence. Several explana-
tions have been suggested including: waning of immuno-
logical response to the aP vaccine, detection bias,
emergence of mutated B. pertussis strains not covered by
the vaccine, and more. All are relevant theories, and
each of them probably contributes to the reemergence
of pertussis. However, none of these seem to adequately
explain the pattern of rise of pertussis disease [12, 13],
suggesting that a key piece of the puzzle is still missing.
As will be shown, the answer to this question likely
rests on a multiplicity of sources of evidence, including
epidemiologic studies, modeling exercises, experimen-
tally derived data using animal models of pertussis
exposure and vaccine responses, and recent insights into
the immunology of pertussis and pertussis vaccines. A
key theme that emerges is whether and to what degree
aP vs. wP vaccines induce mucosal immunity, what the
specific immunological mechanisms are that allow for
that response, and how these differ between the two vac-
cine types.
Analysis
Characteristics of the wP vaccines
The introduction of the wP vaccines in the US in the
1950s yielded a 99% reduction in cases of clinical pertus-
sis [8]. But while the vaccines clearly worked well, the
specific immunological mechanisms that were essential
to their effectiveness were never identified, nor the key
antigens that induced these responses. A reminder of
this ambiguity is the fact that we still do not have a
clearly identified immunologic correlate of protection
for wP vaccines, nor for aP vaccines. It should be noted
that the wP vaccines, by their very nature, include 100 s
or 1000s of non-standardized antigens at varying con-
centrations. Which of these, alone or in combination,
are the essential ones remains enigmatic [14].
But even absent clear understanding of the immun-
ology of wP vaccines, it is still possible to identify ways
in which the wP vaccines appear to offer population
level protection. The British epidemiologists Fine and
Clarkson described the various methodological problems
pertaining to the design and analysis of vaccine studies,
that may contribute to variations in wP vaccine efficacy
estimations [15]. Amongst others, they address perhaps
the most important question of all: what do wP vaccines
protect from? Do they mainly prevent disease? Or do
they also prevent infection, irrespective of symptoms?
Pertussis infection has a spectrum of presentations with
Fig. 1 Pertussis cases in the US, 1940–2012. Data are from the Centers for Disease Control and Prevention via the National Notifiable Diseases
Surveillance System
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the classical “whooping cough” on one end, through
mild illness in re-infected and vaccinated individuals on
the other end. Whether pertussis exists in a true ‘carrier
state’ of asymptomatic infection has never been resolved,
since no carriage studies have ever been conducted.
Studies that assess pertussis vaccine efficacy only against
‘severe’ disease would be predicted to show high efficacy,
which emphasizes the direct effects of the vaccine. Natur-
ally, if including milder or asymptomatic disease, then vac-
cines will show lower efficacy. As been shown by Fine and
Clarkson with epidemiological data from England and
Wales [15] milder cases of pertussis are probably harder
to confirm, as they have a higher chance of being “culture
negative”, and we assume perhaps also induce a milder
serologic response as well. If that indeed is true- this could
give a biased higher efficacy estimation. Most of the effi-
cacy trials were confirming pertussis by culture and/or
serologic response, and were actually focusing on the se-
vere form and direct protection rather than milder or
asymptomatic cases [15, 16].
How the switch from wP to aP vaccines occurred
In 1986 the first placebo-controlled trial of an acellular
vaccine was carried out in Sweden, supported by the
NIH. Sweden was selected because at that time it was
one of the few countries in Europe that did not adminis-
ter wP pertussis vaccines routinely to infants, having
been discontinued several years earlier in the wake of
several highly publicized adverse events [17]. The trial
was conducted in children aged 5–11 months old. 3801
children were given 2 doses of aP vaccine and were
followed for 15 months after the second dose. The aP
vaccine was found to give significant protection against
laboratory confirmed pertussis (by culture or serology
testing), the protection was better against more severe
disease – a clear sign of robust direct effects of the vac-
cine – but the vaccine efficacy was not significant when
cases that were not confirmed by laboratory tests were
included [18]. Was this because these non-confirmed
cases were in fact due to other pathogens than B. pertus-
sis? Or, was this because the vaccine had limited effect
in preventing mild disease and asymptomatic carriage
(and therefor transmission)?
Another interesting fact about the environment in
which the efficacy trials were held, is that at the time the
clinical trial for aP were conducted, the population aged
7 years and older had already been vaccinated with wP
vaccine, and presumably had some degree of protection
against pertussis. In other words, the trial was not con-
ducted in a vaccine-free environment that would allow
to accurately assess the efficacy of the vaccine, but rather
was influenced by the fact that there was some grade of
protection in the majority of the population that could
serve as the reservoir of pertussis.
A summary of the aP vaccine efficacy trials is shown
in Table 1. The aP vaccines used in each trial contained
different concentrations of antigens. All contained pro-
teins thought to produce protective immunity: the per-
tussis toxin (PT), which is believed to be the major
virulence factor, is found in all the vaccines. But they
also contained other various antigens in different con-
centrations and combinations, such as filamentous
hemagglutinin (FHA), Pertactin (PRN), and fimbriae
(FIM) [19].
The pivotal studies that ultimately led to the licen-
sure and adoption of aP vaccines were conducted in
Italy and Sweden, both selected because they had not
incorporated pertussis vaccines into their infant
Table 1 Efficacy trials of acellular pertussis vaccine [10, 64, 65]
Study year Study location/name Design and methods Number of participants Comments.
1985 [18] Sweden, Stockholm Double blind placebo controlled (compared
two Japanese aP vaccines)




Double blind placebo controlled (compared DT/DTP) 3450 No wP control
3 dose schedule.
1992 [67] Germany, Mainz Passive monitoring of household contacts 360 contacts 3 dose schedule
1992 [68] Sweden, Stockholm Double blind placebo controlled (two-compenent
aP/five component aP/wP/DT)
24,336 wP control – (Conaught)
3 dose schedule
1992 [69] Italy Double blind placebo controlled
(aP/wP/DT)
14,751 wP control – (Conaught)
3 dose schedule
1993 [70] Germany, Munich Case control study
(aP/wP/DT/no vaccine)
16780 3 dose schedule
1990 [71] Senegal -Double blind placebo controlled
-Household contact (aP/wP)
4181 No placebo control
3 dose schedule
Late 90′s [72] Germany, Erlangen Prospective study,
2 groups randomized to aP or wP, third
group (not randomized) received DT.
4 dose schedule
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schedules. In both, aP was compared to wP and
against a placebo using a blinded, randomized con-
trolled design, with culture or serology confirmed
clinical pertussis as the primary endpoint. And in
both cases, the aP vaccines proved to have far super-
ior tolerability, improved safety, and yielding higher
concentrations of antibodies against pertussis toxin
compared with wP vaccines. In other words, a seem-
ingly clear ‘win’ for the aP vaccines.
In light of the subsequent rise in pertussis following
the switch to aP vaccines, it is worth considering how it
was that these vaccines, initially so promising, ultimately
proved so disappointing. The following features all likely
contributed to favoring the efficacy of aP vaccines over
that of wP.
First, when the different aP vaccines were compared to
a wP vaccine and placebo, in the majority of the studies
the whole cell vaccine was found to be more immuno-
genic. Only in two trials the aP vaccine had higher effi-
cacy compared to the wP vaccine and those two trials
were the pivotal trials leading the support to switch to
the aP vaccine. Those were the trials in which the poorly
immunogenic wP vaccine manufactured by Connaught,
was used [10]. That, of course, would bias the study to
show superiority of the aP vaccine.
Second, is that the immunogenicity of each vaccine
was estimated by measurements of antibodies against
PT and FHA, two of the antigens present in high
concentrations in the aP vaccine. And indeed, far su-
perior serologic responses, defined as a four-fold in-
crease in antibodies titers, was seen to those antigens
after immunization with the aP vaccines than the wP
vaccines. Unfortunately, the implication of such re-
sponse is poorly understood since we did not then,
and do not now, have a clear correlate of protection
for wP or aP vaccines. And since wP vaccines are a
mixture of literally thousands of antigens, plus the
lipopolysaccharide in the bacterial membrane, the pre-
cise mechanism underlying how wP vaccines worked
was never elucidated. While PT and FHA are present,
they are not present in the same concentrations in a
wP vaccine as in an aP vaccine, and their relative im-
portance to the overall protective effect of the vaccine
is difficult to parse. Therefore showing that an aP
vaccine produces higher anti-PT or anti-FHA anti-
bodies than wP vaccines presupposes that these anti-
gens are what drive immunologic protection, which
was not shown to be true.
Third, the studies eliminated consideration of long
term response to the vaccine, and there was limited
evaluation of the vaccine overtime.
And lastly, the studies only measured the direct, not
indirect, effects of each vaccine. As noted earlier, an im-
portant quality of a vaccine is its ability to induce herd
immunity by preventing transmission of infection to un-
immunized populations (i.e. newborns). The trials were
not designed to evaluate that quality of the aP vaccines.
Hypotheses for the resurgence of pertussis in the aP
vaccine era
Over the years, a number of explanations for the re-
surgence have been postulated. These include: 1) De-
tection bias; 2) Poor persistence of antibodies; and 3)
Evolutionary shifts among B. pertussis (waning or
‘leaky’ efficacy). Each will be discussed in turn, and
while all may contribute, collectively they fail to fully
explain the observed patterns of the pertussis
resurgence.
1) Detection bias
B. pertussis is fastidious and intrinsically difficult to
grow in culture. Moreover, cultures can be rendered
‘sterile’ by antibiotics, leading one to miss actual
cases of pertussis. In the last 25 years the use of
PCR has revolutionized pertussis detection,
yielding results that are far more sensitive and
specific than culture, and robust against the
masking effects of antibiotic exposure. However,
the down side to PCR’s sensitivity is that it
detects a lot more pertussis, and in particular,
identifies a higher burden of milder and atypical
cases than did traditional culture methods
[12, 20, 21]. It has been suggested that PCR may
have revealed a hidden burden of disease,
meaning that much of the apparent rise in cases
is artifactual, and merely a reflection of improved
detection methods [22–24]. While that argument
has merit, and likely does explain the shift to a
milder spectrum of illnesses being identified, it
does not fully explain the observed data. In
particular, increases in the rates of severe and
fatal pertussis among infants have been recorded
in the US and elsewhere after the switch to
aP vaccines. In recent analyses, the WHO has
determined that the rise in pertussis is real, and
not artifactual [25].
2) Poor persistence
The biological factors by which immunity to
pertussis is achieved and maintained are
complicated and poorly understood. Following
infection and vaccination, antibodies against many
B. pertussis antigens develop. It was postulated in
the past that natural infection with B. pertussis
caused close to lifelong immunity, but data
regarding adult infection in unvaccinated
populations indicate that immunity after natural
infection wanes over time. Studies of unvaccinated
children in the Netherlands and Senegal showed
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that reinfection was not uncommon and the
duration of protection after first episode of
pertussis lasted at least 7–10 years, but was not
permanent [26]. However, this phenomenon
appears to be far more pronounced with aP
vaccines. This was first documented in a long
term follow up of the Swedish children first to
be vaccinated with the aP vaccine, whose
susceptibility to pertussis appeared to have faded
by 7–8 years of age [27]. More recent studies
show that by 5 years after completion of a DTaP
series, children were up to 15 times more likely to
acquire pertussis compared to the first year after the
series. Studies have also documented rapid decline in
pertussis antibodies within as few as 2–3 years of the
most recent aP vaccination, often to pre-vaccination
levels [28–32] and although antibody levels alone are
not necessarily indicative of waning immunity, in this
case given the higher risk of infection after aP vaccine
with time, it is strongly suggestive of it. When
comparing the immunologic response to aP and
wP, adolescents that were previously vaccinated
with aP were at much higher risk (almost 6 times
higher risk) to be infected with pertussis than
those vaccinated with wP [33]. One study, exam-
ining US infants during the transition years from
aP to wP vaccines, found that receipt of even one
dose of wP vaccine in an otherwise purely aP vac-
cine series, led to significantly improved protec-
tion than infants who only received the aP
vaccines [34].
Thus, it is clear that lack of persistence of
immunity after aP vaccine, and to some extent
also after wP vaccine and natural infection, plays
an important role in maintaining pertussis within
populations. But logically, if the problem is merely
poor persistence, one would anticipate that
increases would occur first among adolescents,
and latest among younger children. However,
the pertussis rise was synchronous across all
age groups, meaning that disease transmission
was occurring across all age groups in parallel
[13, 35]. So while an important factor in the
pertussis resurgence, other data suggest that this
is only one piece of the puzzle.
3) Evolutionary shifts among B. pertussis (waning or
‘leaky’ efficacy)
Just as exposure to antibiotics creates a selective
evolutionary pressure for bacteria to develop
resistance to antibiotics, so too can vaccines exert
pressure for bacteria to evolve to different
antigenic isoforms of proteins included in vaccines
[36–41]. In the case of B. pertussis, this
adaptation has been clearly demonstrated to occur
via at least three known mechanisms – antigenic
shift away from antigens covered by the aP
vaccine, deletion of antigens covered by the aP
vaccine, and over-production of antigenic targets.
In a comprehensive study spanning over the past
100 years, Bart et al. [42] analyzed genome of 343
disease causing B. pertussis isolates collected from
19 countries around the world. The major
changes in antigen gene alleles were from ptxA2
to ptxA1, fim2-1 to fim2-2 and ptxP1 to ptxP3: in
each case a shift from the specific antigen alleles
included in aP vaccines to alleles that are not
covered by the vaccine. Mooi et al. [36] found in
the late 1980’s that B. pertussis strains emerged
with increased production of pertussis toxin. In
this case, the PT promotor showed a relatively
high degree of polymorphism, suggesting the PT
over-production has adaptive value. These new
strains, carrying the ptxP3 allele, were more virulent
to humans with higher incidence of hospitalizations
and deaths, and this appears to have reflect that the
ptxP3 promoter far over-expresses pertussis toxin
compared with the ptxP1 promoter [36, 37, 43–46].
An even more definitive evolutionary escape route has
been noted from multiple laboratories regarding per-
tussis isolates that stopped expressing one or more of
the aP antigen genes entirely. This includes, in isola-
tion or combinations, Pertactin, FHA and more re-
cently PT. [45, 47–49] Remarkably, PRN expressing B.
pertussis strains have entirely disappeared from the
US, and the finding of PT-minus strains is surprising
given assumptions that pertussis toxin was an obliga-
tory virulence factor.
But as with the issue of poor persistence,
evolutionary shifts to evade aP vaccines do not
appear to satisfactorily explain the pertussis
resurgence. One problem with this explanation is
Sweden, where a pertussis toxin-only, mono-valent
aP vaccine has retained efficacy for over 20 years,
despite the accumulation of non-aP vaccine allele
strains of pertussis. Another problem is the timing
of these shifts, which accumulate gradually with
time. By contrast, the increase in pertussis disease
in countries that switched to aP vaccines has, in
each case, occurred after a now stereotypical lag
of 5–10 years, not at all the pattern that one
would expect if the problem was due to the slow
acquisition of mutations. Moreover, the degree to
which escape mutants of pertussis contribute to
the overall resurgence has not been established.
Thus as with detection bias and poor persistence,
evolution may be a contributing factor
to pertussis resurgence, but something is still
missing.
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Recent insights from mathematical models of pertussis
transmission
Probably one of the most significant finding from recent
years is that aP vaccines provide strong direct protection
against severe disease (at least in the short term), but
may have relatively little indirect effect on transmission.
The lack of protection from transmission of the per-
tussis vaccines was first hypothesized by Fine and Clark-
son in 1982 [50]. Fine and Clarkson contrasted the
inter-epidemic cycle length during a period of high wP
uptake in the UK against a subsequent period of low wP
uptake in the UK (due to concerns from serious adverse
events). Mathematical modules of epidemiology of per-
tussis consistently show that the disease peaks every 3–4
years. Fine and Clarkson found no change in the cycle
length and therefore concluded that wP did not impede
transmission, i.e., that wP lacked herd effect.
This conclusion was influential but appears to have
been flawed for several reasons. First and foremost,
Fine and Clarkson looked at the epidemic cycle
lengths over time using national case averages from
the UK. But that assumes that pertussis transmission
is occurring synchronously, which is actually unlikely
to be the case. Failure to account for local transmis-
sion epidemics in aggregate data would tend to blunt
the shapes of epidemic cycles, and could obscure true
changes in the cycle length. To account for this, in
2000 Rohani et al. [51] compared the inter-epidemic
cycles before and after the introduction of wP pertus-
sis vaccine in different cities in the UK, using each
city as its own comparator. In each case they found
that the interepidemic cycle was increased by 1.5-
2.5 years by the introduction of wP vaccines. This ob-
servation has now been replicated in 64 countries
around the world [52].
Following this same reasoning, but taking the switch
instead from wP to aP vaccines as the reverse test case,
Althouse and Scarpino, using a technique called ‘wavelet
analysis’ (essentially a way of looking at multiple small
outbreaks of disease over time), found a re-contraction
of the interepidemic cycle length after the wP to aP
switch. That is precisely what would be expected if wP
vaccine block transmission and disease, but aP vaccines
only block symptomatic disease, and have little impact
on transmissions [13].
In a parallel analysis, Althouse and Scarpino examined
the pace of genetic mutation among observed cases.
Their surprising finding was that genetic mutation
seemed to outpace known routes of transmission, sug-
gesting that the extra genetic diversity reflected longer
transmission pathways between observed cases, and
hence the existence of asymptomatic carriage and trans-
mission. This was a seminal observation, and we will re-
turn to this issue subsequently.
Indirectly, these models also shed light on the surpris-
ing failure of Cocooning to protect young infants from
pertussis. Cocooning refers to the practice of administer-
ing Tdap to all household contacts of a newborn, as a
means of providing an immunologically safe cocoon,
shielding the newborn from infectious contacts. How-
ever, the success of Cocooning presupposes that aP vac-
cines block carriage and asymptomatic transmission in
addition to blocking disease. This practice proved sur-
prisingly unsuccessful in randomized controlled trials.
This seems counterintuitive if we assume that aP vac-
cines block transmission and disease, but are exactly
what would be expected if they permit silent infections
and continued transmission [53, 54].
In summary, the mathematical models suggest that wP
induced protection against transmission to a significant
extent, meaning that they blocked transmission, offered
herd immunity, and likely did so by blocking carriage,
whereas the aP vaccine had no or minimal impact on
blocking infections or transmissions, afforded poor herd
effect, and, we would predict, do not block carriage.
Differential impact of aP and wP vaccines in a baboon
model
Probably the strongest evidence that aP vaccine fail to
protect from transmission came from a series of studies
by Warfel and Merkel at the US FDA using a non-
human primate model involving infant baboons [55–58].
With Warfel’s Baboon model, we are now able to bet-
ter understand the pathogenesis and the immune re-
sponse to the disease and to the different vaccines.
Baboons that were vaccinated with aP or wP vaccines
were later challenged with aerosols of B.pertussis. Both
sets of vaccinated baboons remained clinically asymp-
tomatic, while unvaccinated control baboons became se-
verely ill, and developed profound lymphocytosis, a
common finding among human infant pertussis disease,
and known to be mediated by pertussis toxin specifically
(Fig. 2). This confirmed that aP and wP vaccines both
provide excellent direct protection against disease (at
least in the short term), and that pertussis disease in the
animal model was a valid proxy for disease in human
infants.
But when looking beyond disease to the vaccines’ effi-
cacy vs. infection, the aP and wP vaccines diverged
sharply. The un-vaccinated and aP vaccinated baboons
remained colonized for an average of 33–35 days before
clearing. By contrast, the wP vaccinated baboons cleared
carriage after only 18 days, and had lower bacterial con-
centrations than the aP and vaccine-naïve animals.
Taking this one step further, when two aP vaccinated
baboons and one unvaccinated baboon were co-housed
in the same cage with an unvaccinated and infected ani-
mal, all three animals were colonized with pertussis
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within 10 days, further evidence that aP did not protect
against colonization (Fig. 3). Taking this in reverse, when
an aP vaccinated baboon was infected with B. pertussis,
and then co-housed with a naïve baboon, the naïve ba-
boon quickly became infected and became symptomatic
(Fig. 4). Collectively, these experiments showed that both
wP and aP vaccines prevent clinical disease, but that aP
vaccines do not block infections. Moreover, aP vacci-
nated, asymptomatic but infected animals are quite cap-
able of infecting other animals, and thereby participating
in chains of transmission.
Immunological insights into pertussis infections and
vaccine responses
When looking in to the Immunological processes in-
volved in conferring mucosal sterility, a recent discovery
sheds more light and adds another missing piece to our
puzzle. Until recently, the two classical known pathways
for T helper cells were believed to be either the Th1 or
the Th2 pathways. The former response primes T cells
to control intracellular infections, such as tuberculosis;
while the latter, Th2, optimizes anti-body responses
against extracellular targets, and is involved in responses
to parasitic infections. However, this dichotomy feels in-
complete, since it fails to accounts for many T-cell medi-
ated immune responses that do not neatly fit into either
paradigm, many of which became clear as a consequence
of the HIV/AIDS pandemic.
More recently, a third pathway was discovered of an
independent lineage of cells, called the Th17 cells (so
named due to dominant cytokine that drives cells down
this pathway, interleukin 17). Of relevance, Th17 cells
are found in the lungs, the gut mucosa, the skin, and
play a critical role in mucosal immunity and host
defense against extracellular pathogens [59, 60].
Following this logic, Warfel et al. also showed that in-
fection with B. pertussis induced a pure Th17 response,
and these cells were found to play a distinct role in the
pathogenesis of B. pertussis infection [61]. Similarly, wP
vaccines also induce a Th17 dominant responses (with a
lesser Th1 contribution). By contrast aP vaccines only
produced a Th2 response [56, 58, 62, 63].
Conclusions
Table 2 summarizes the major differences between wP
vaccine and aP vaccine as the evidence of the last
75 years suggest.
The resurgence of pertussis likely has many contribut-
ing factors. And while detection bias, poor persistence,
and leaky vaccine efficacy due to evolutionary shifts
likely contribute to varying degrees in the pertussis re-
surgence, it seems far more likely that the key factor is
instead immunologic. As with the conjugated protein-
polysaccharide vaccines, the overall effectiveness of a
pertussis vaccine when used at scale in a population is a
function of direct and indirect effects. The lack of
Fig. 2 Outcomes of experimental exposure to pertussis among aP or wP vaccinated or unvaccinated infant baboons. Three groups of infant
baboons were exposed to infectious aerosols of B. pertussis: unvaccinated control animals; animals vaccinated using acellular pertussis vaccines;
animals vaccinated using whole cell pertussis vaccines. The vaccinated animals completed a full vaccination series and were allowed time to fully
seroconvert before exposure. The two vaccinated groups of animals both remained asymptomatic, whereas the unvaccinated animals developed
clinical disease. However, nasopharyngeal sampling of the three groups showed that the aP and unvaccinated animals both were infected with
similar densities of pertussis bacteria and for similar durations. By contrast, the wP vaccinated animals were more resistant to carriage, and carried
bacteria for shorter periods. This showed that wP and aP vaccinations induce very different mucosal immune responses, with the former
protecting against infection and disease, and the latter only preventing clinical disease, but not infection
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sterilizing mucosal immunity following aP vaccinations
appears to be a critical limitation to these vaccine’s over-
all effectiveness, and in our view may be the most im-
portant factor of all in accounting for the resurgence.
If so, the implications of this inference are quite pro-
found. The resurgence of pertussis in the past 2 decades
is at once a public health and a public relations crisis.
Vaccine hesitancy rates are rising, and the population is
increasingly skeptical about professional pronounce-
ments regarding vaccine policy. With the introduction
and expanded use of aP vaccines into the population
failing to control the rise in pertussis incidence, it seems
Fig. 4 Infections from an asymptomatic vaccinated to unvaccinated animal. The first experiment showed that an unvaccinated but infected animal is
capable of infecting an aP vaccinated animal. This experiment approaches this dynamic in reverse: here an aP vaccinated animal was infected with B.
pertussis and then co-housed with an unvaccinated animal. Despite being asymptomatic, the aP vaccinated animal quickly infected the vaccine naïve
control animal, who developed clinical disease as well as nasopharyngeal carriage showing that infection had occurred. This proved that, despite being
symptom free, aP vaccinated animals can become infected with pertussis, and are able to transmit to unvaccinated animals. In other words, aP vaccination
only prevented clinical disease, but did not prevent animals from being infectious and contributing to chains of transmission
Fig. 3 Outcome of exposure to infected animal by vaccination status. Here, an infected unvaccinated animal was co-housed with three initially
uninfected animals, one of which was unvaccinated, while the other two had received aP vaccinations. All three animals became infected based
on nasopharyngeal sampling, though only the unvaccinated animal showed signs of clinical illness. This showed that infection due to exposure
to an infected animal can transmit B. pertussis (a more realistic model than exposure to aerosols). But again, while aP vaccinations blocked clinical
disease, they did not prevent infection
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increasingly likely that radical solutions will be required.
This may include the resumption of wP vaccinations in
some part of the infant schedule, or even the develop-
ment of an entirely new pertussis vaccine. While it is too
soon to know how this will play out, understanding how
any new or improved pertussis vaccine affects mucosal
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